Cryptotanshinone Attenuated Pathological Cardiac Remodeling In Vivo and In Vitro Experiments

Area of Science:

• Cardiovascular Biology
• Pharmacology
• Molecular Medicine

Background:

• Cardiac remodeling is a precursor to various cardiomyopathies, lacking targeted preventative treatments.
• Understanding the molecular mechanisms underlying cardiac remodeling is crucial for developing effective therapies.

Purpose of the Study:

• To evaluate the efficacy of Cryptotanshinone (CTS) in preventing and treating cardiac remodeling.
• To elucidate the underlying molecular mechanisms of CTS action in cardiac remodeling.

Main Methods:

• A pressure-overload mouse model was established using aortic banding (AB) surgery.
• Cardiac function was assessed via echocardiography and pressure-volume loops.
• Histological analysis (HE, PSR) and molecular pathway analysis were performed on heart tissues.
• In vitro studies utilized neonatal rat cardiomyocytes (NRCMs) and cardiac fibroblasts (CFs).

Main Results:

• CTS treatment improved cardiac function and reduced cardiac hypertrophy and fibrosis in the mouse model.
• CTS inhibited the STAT3 and TGF-β/SMAD3 signaling pathways.
• In vitro, CTS prevented AngII-induced cardiomyocyte hypertrophy and TGF-β-induced myofibroblast activation by inhibiting STAT3 phosphorylation.
• STAT3 overexpression via AAV9 negated the protective effects of CTS against pressure overload.

Conclusions:

• Cryptotanshinone (CTS) shows potential in attenuating pathological cardiac remodeling.
• The protective effects of CTS are mediated through the inhibition of the STAT3 signaling pathway.
• Targeting the STAT3 pathway presents a viable therapeutic strategy for cardiac remodeling.